A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Advanced Hepatocellular Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

City of Hope, Duarte, California, United States
Contact: Study coordinator (Amro Tahoun) · amtahoun@coh.org · 626-218-0115
Contact: Study coordinator (Edwin Smura) · esmura@coh.org · 626-218-0115
Sylvester Comprehensive Cancer Center, Miami, Florida, United States
Contact: Study coordinator (Lauren Miro) · lem183@med.miami.edu
University of Chicago, Chicago, Illinois, United States
Contact: Study coordinator (Asha Woodfolk) · asha.woodfolk@uchicagomedicine.org
Levine Cancer Institute, Charlotte, North Carolina, United States
Contact: Study coordinator (Kelly Bumgarner) · Kelly.Bumgarner@atriumhealth.org
UT Southwestern, Dallas, Texas, United States
Contact: Study coordinator (Ashley Bird) · ashley.bird@utsouthwestern.edu
Contact: Study coordinator (Shazeb Munawar) · Shahzeb.munawar@utsouthwestern.edu · 214-645-9883
MD Anderson Cancer Center, Houston, Texas, United States
Contact: Study coordinator (Z. Esra Cobanoglu) · ZECobanoglu@mdanderson.org
Fred Hutchinson Cancer Center, Seattle, Washington, United States
Contact: Study coordinator (Sonia Wadhera) · sgoyal@fredhutch.org
UHN - Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Contact: Study coordinator (Ama Chandrasiri) · ama.chandrasiri@uhn.ca

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE2

Shanghai, China

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

Solid Tumors · Non-small Cell Lung Cancer · Renal Cell Carcinoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Bengbu, China · Beijing, China

Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC

Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE2

Guangzhou, China

bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC

Liver Diseases · Hepatocellular Carcinoma · Immunotherapy

Abroad (travel likely)Recruiting

Guanzhou, China